Jeevan Scientific Technology today said it has received approval from the central drug regulator for its Hyderabad-based clinical pharmacology centre for three years.
The company's clinical pharmacology centre that conducts bioavailability/bioequivalence studies, has been approved by the office of Drug Controller General of India (DCGI) on December 16, 2016, for a period of three years, Jeevan Scientific Technology said in a filing to BSE.
This centre has four independent clinics having a total capacity of 132 beds to facilitate end-to-end bioequivalence studies, it added.
Shares of Jeevan Scientific Technology today closed at Rs 50.65 on BSE, up 7.20 per cent from previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
